Blood cancers

Clarithromycin fails to show benefit in Phase 3 trial of multiple myeloma therapy

The addition of clarithromycin to treatment with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma did not significantly improve progression-free survival in a phase 3 trial. It contrasts with previous case-control analyses which had suggested better response rates when including the macrolide antibiotic to the regimen in patients who were ineligible for stem ...

Already a member?

Login to keep reading.

© 2021 the limbic